HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

BMRN: Biomarin Pharma Inc - Stock News Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Company News |  Zacks Commentary
BIOMARIN PHARMA INC (NASD)
BMRN 16.74 0.07 (0.42%) Vol.  8,815 9.00 CST

Nov 24, 2009 BioMarin to Present at the NASDAQ OMX 23rd Investor Program
Nov 13, 2009 Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
Nov 05, 2009 United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
Nov 05, 2009 Financial & Company Analysis on CPST, ERIC, CVBF, BMRN, HLIT and CDNSfrom TheFortuneFinancial.com
Nov 04, 2009 BioMarin to Present at the Credit Suisse Healthcare Conference
Oct 29, 2009 BUYINS.NET: BioMarin Pharmaceutical (BMRN) Up After BUYINS.NET Report Predicted Strength After Earnings
Oct 29, 2009 BioMarin Pharmaceutical (BMRN) NewsBite - BMRN Rises on Earnings
Oct 29, 2009 BioMarin (BMRN) Upgrade Alert, Watch for 17.5% Technical Uptrend Continuation
Oct 29, 2009 Analyst Upgrades for October 29th
Oct 28, 2009 BioMarin Pharmaceutical Narrows Revenue Guidance Below Estimates
Oct 28, 2009 BioMarin Announces Third Quarter 2009 Financial Results
Oct 28, 2009 BioMarin acquires Huxley Pharmaceuticals
Oct 28, 2009 Conference Calls Today: 5-8 P.M. EDT
Oct 27, 2009 BioMarin to Present at the Oppenheimer Healthcare Conference
Oct 27, 2009 BMRN: Announces Acquisition of Huxley Pharmaceuticals
 
ZACKS COMMENTARY FOR BMRN
Oct 27, 2009 Zacks Blog: BioMarin Purchases Huxley
Sep 23, 2009 Zacks Blog: BioMarin Begins Mid-Stage Trial
Sep 17, 2009 Zacks Equity Research: Report for BMRN
Jul 31, 2009 Zacks Blog: BioMarin Beats Zacks Estimates
May 04, 2009 Zacks Blog: BioMarin Top-Line Diminishing
Feb 20, 2009 Zacks Blog: BioMarin Downgraded to Hold
Jan 26, 2009 Zacks Analyst Interviews: Biotech Industry
Jan 23, 2009 Zacks Blog: Biotech Industry
Jan 06, 2009 Zacks Blog: BioMarin a Buy with a $28 Target
Dec 05, 2008 Zacks Analyst Interviews: Biotechnology Industry
Dec 04, 2008 Zacks Blog: Biotechnology Industry

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research